Video

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.

Transcipt (slightly modified)

What are your thoughts on providers taking on 2-sided risk?

The 2-sided risk model, I think like any challenge or any strategy, is we want to know all sides. So, what’s the upside, what’s truly the downside, where’s our floor, and how high can our ceiling go? I think we’ll know that as OCM starts to look at reconciliation and looking at numbers and data distributions. I think we’ll find that some of the oncology care models then will put their toes in the water and try to see what a risk model would look like. I think as long as these risk models are outcome based and the goal is to improve quality, I don’t think that anyone would ever want an oncology practice to not do well and go bankrupt because of a payment model that’s developed. Obviously if that happens, we’ve done something wrong and we need to fix it.

Related Videos
ATS 2025
Bridgette J. Picou, LVN, ACLPN, The Well Project
Marla Black Morgan, MD, Phoebe Neurology Associates
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo